Global Recombinant Peptide Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Peptide Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
A recombinant peptide therapy is produced through recombinant DNA technology. This involves inserting the DNA encoding the peptide into bacterial or mammalian cells, expressing the peptide in these cells and then purifying it from them.
Recombinant Peptide report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Peptide market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Oncology and Blood Disorders are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Peptide industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Peptide key manufacturers include Sandoz Pharma, Stada Arzneimittel, Amgen, Hospira, Actavis, Cipla Ltd., Wockhardt Ltd. and Biocon Ltd., etc. Sandoz Pharma, Stada Arzneimittel, Amgen are top 3 players and held % sales share in total in 2022.
Recombinant Peptide can be divided into Glucagon, Calcitonin and Other,, etc. Glucagon is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Peptide is widely used in various fields, such as Oncology, Blood Disorders, Infectious Diseases and Autoimmune Diseases, etc. Oncology provides greatest supports to the Recombinant Peptide industry development. In 2022, global % sales of Recombinant Peptide went into Oncology filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Peptide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Sandoz Pharma
Stada Arzneimittel
Amgen
Hospira
Actavis
Cipla Ltd.
Wockhardt Ltd.
Biocon Ltd.
Segment by Type
Glucagon
Calcitonin
Other
Oncology
Blood Disorders
Infectious Diseases
Autoimmune Diseases
Other
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Peptide market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Peptide, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Peptide industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Peptide in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Peptide introduction, etc. Recombinant Peptide Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Recombinant Peptide market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Recombinant Peptide report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Peptide market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Oncology and Blood Disorders are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Peptide industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Peptide key manufacturers include Sandoz Pharma, Stada Arzneimittel, Amgen, Hospira, Actavis, Cipla Ltd., Wockhardt Ltd. and Biocon Ltd., etc. Sandoz Pharma, Stada Arzneimittel, Amgen are top 3 players and held % sales share in total in 2022.
Recombinant Peptide can be divided into Glucagon, Calcitonin and Other,, etc. Glucagon is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Peptide is widely used in various fields, such as Oncology, Blood Disorders, Infectious Diseases and Autoimmune Diseases, etc. Oncology provides greatest supports to the Recombinant Peptide industry development. In 2022, global % sales of Recombinant Peptide went into Oncology filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Peptide market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sandoz Pharma
Stada Arzneimittel
Amgen
Hospira
Actavis
Cipla Ltd.
Wockhardt Ltd.
Biocon Ltd.
Segment by Type
Glucagon
Calcitonin
Other
Segment by Application
Oncology
Blood Disorders
Infectious Diseases
Autoimmune Diseases
Other
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Peptide market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Peptide, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Peptide industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Peptide in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Peptide introduction, etc. Recombinant Peptide Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Recombinant Peptide market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.